APO RESEARCH · REPORT
Liposome and Lipid Nanoparticle Finished Pharmaceuticals
Selected research
Industry Research
Liposome and Lipid Nanoparticle Finished Pharmaceuticals Industry Research Report 2026
Market perspective
The global Liposome and Lipid Nanoparticle Finished Pharmaceuticals market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Liposome and Lipid Nanoparticle Finished Pharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Liposome and Lipid Nanoparticle Finished Pharmaceuticals market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Liposome and Lipid Nanoparticle Finished Pharmaceuticals market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Liposome and Lipid Nanoparticle Finished Pharmaceuticals include Takeda, Teva, Sun Pharmaceutical, Johnson & Johnson, Chiesi Farmaceutici, Gilead Sciences, Zydus Cadila, TTY Biopharma and Sayre Therapeutics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Liposome and Lipid Nanoparticle Finished Pharmaceuticals market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Liposome and Lipid Nanoparticle Finished Pharmaceuticals.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market by Company
Takeda
Teva
Sun Pharmaceutical
Johnson & Johnson
Chiesi Farmaceutici
Gilead Sciences
Zydus Cadila
TTY Biopharma
Sayre Therapeutics
Pacira
Luye Pharma
Leadiant Biosciences
Kinyond
Jazz
Ipsen
Fudan-Zhangjiang
CSPC
Bausch Health
Alnylam
Acrotech Biopharma
Liposome and Lipid Nanoparticle Finished Pharmaceuticals Segment by Type
Liposomes Drugs
Lipid Nanoparticle Drugs
Liposome and Lipid Nanoparticle Finished Pharmaceuticals Segment by Application
Hospital
Retail Pharmacy
Other
Liposome and Lipid Nanoparticle Finished Pharmaceuticals Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposome and Lipid Nanoparticle Finished Pharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liposome and Lipid Nanoparticle Finished Pharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposome and Lipid Nanoparticle Finished Pharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Liposome and Lipid Nanoparticle Finished Pharmaceuticals companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Type (2021-2026) & (US$ Million)
Table 6. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share by Type (2021-2026)
Table 7. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 8. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share by Type (2027-2032)
Table 9. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Application (2021-2026) & (US$ Million)
Table 10. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share by Application (2021-2026)
Table 11. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 12. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share by Application (2027-2032)
Table 13. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 14. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Region (2021-2026) & (US$ Million)
Table 15. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Share by Region (2021-2026)
Table 16. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Forecasted Market Size by Region (2027-2032) & (US$ Million)
Table 17. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Share by Region (2027-2032)
Table 18. Liposome and Lipid Nanoparticle Finished Pharmaceuticals Industry Trends
Table 19. Liposome and Lipid Nanoparticle Finished Pharmaceuticals Industry Drivers
Table 20. Liposome and Lipid Nanoparticle Finished Pharmaceuticals Industry Opportunities and Challenges
Table 21. Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Restraints
Table 22. Global Top Liposome and Lipid Nanoparticle Finished Pharmaceuticals Players by Revenue (US$ Million) & (2021-2026)
Table 23. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share by Players (2021-2026)
Table 24. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Industry Players Ranking, 2024 VS 2025 VS 2026
Table 25. Global Key Players of Liposome and Lipid Nanoparticle Finished Pharmaceuticals, Headquarters and Area Served
Table 26. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 31. North America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2021-2026) & (US$ Million)
Table 32. North America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2027-2032) & (US$ Million)
Table 33. Europe Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 34. Europe Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2021-2026) & (US$ Million)
Table 35. Europe Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2027-2032) & (US$ Million)
Table 36. Asia Pacific Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Asia Pacific Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Region (2021-2026) & (US$ Million)
Table 38. Asia Pacific Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2027-2032) & (US$ Million)
Table 39. South America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 40. South America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2021-2026) & (US$ Million)
Table 41. South America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2027-2032) & (US$ Million)
Table 42. Middle East & Africa Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 43. Middle East & Africa Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2027-2032) & (US$ Million)
Table 45. Takeda Company Information
Table 46. Takeda Business Overview
Table 47. Takeda Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 48. Takeda Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 49. Takeda Recent Developments
Table 50. Teva Company Information
Table 51. Teva Business Overview
Table 52. Teva Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 53. Teva Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 54. Teva Recent Developments
Table 55. Sun Pharmaceutical Company Information
Table 56. Sun Pharmaceutical Business Overview
Table 57. Sun Pharmaceutical Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 58. Sun Pharmaceutical Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 59. Sun Pharmaceutical Recent Developments
Table 60. Johnson & Johnson Company Information
Table 61. Johnson & Johnson Business Overview
Table 62. Johnson & Johnson Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 63. Johnson & Johnson Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 64. Johnson & Johnson Recent Developments
Table 65. Chiesi Farmaceutici Company Information
Table 66. Chiesi Farmaceutici Business Overview
Table 67. Chiesi Farmaceutici Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 68. Chiesi Farmaceutici Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 69. Chiesi Farmaceutici Recent Developments
Table 70. Gilead Sciences Company Information
Table 71. Gilead Sciences Business Overview
Table 72. Gilead Sciences Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 73. Gilead Sciences Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 74. Gilead Sciences Recent Developments
Table 75. Zydus Cadila Company Information
Table 76. Zydus Cadila Business Overview
Table 77. Zydus Cadila Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 78. Zydus Cadila Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 79. Zydus Cadila Recent Developments
Table 80. TTY Biopharma Company Information
Table 81. TTY Biopharma Business Overview
Table 82. TTY Biopharma Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 83. TTY Biopharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 84. TTY Biopharma Recent Developments
Table 85. Sayre Therapeutics Company Information
Table 86. Sayre Therapeutics Business Overview
Table 87. Sayre Therapeutics Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 88. Sayre Therapeutics Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 89. Sayre Therapeutics Recent Developments
Table 90. Pacira Company Information
Table 91. Pacira Business Overview
Table 92. Pacira Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 93. Pacira Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 94. Pacira Recent Developments
Table 95. Luye Pharma Company Information
Table 96. Luye Pharma Business Overview
Table 97. Luye Pharma Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 98. Luye Pharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 99. Luye Pharma Recent Developments
Table 100. Leadiant Biosciences Company Information
Table 101. Leadiant Biosciences Business Overview
Table 102. Leadiant Biosciences Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 103. Leadiant Biosciences Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 104. Leadiant Biosciences Recent Developments
Table 105. Kinyond Company Information
Table 106. Kinyond Business Overview
Table 107. Kinyond Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 108. Kinyond Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 109. Kinyond Recent Developments
Table 110. Jazz Company Information
Table 111. Jazz Business Overview
Table 112. Jazz Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 113. Jazz Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 114. Jazz Recent Developments
Table 115. Ipsen Company Information
Table 116. Ipsen Business Overview
Table 117. Ipsen Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 118. Ipsen Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 119. Ipsen Recent Developments
Table 120. Fudan-Zhangjiang Company Information
Table 121. Fudan-Zhangjiang Business Overview
Table 122. Fudan-Zhangjiang Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 123. Fudan-Zhangjiang Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 124. Fudan-Zhangjiang Recent Developments
Table 125. CSPC Company Information
Table 126. CSPC Business Overview
Table 127. CSPC Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 128. CSPC Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 129. CSPC Recent Developments
Table 130. Bausch Health Company Information
Table 131. Bausch Health Business Overview
Table 132. Bausch Health Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 133. Bausch Health Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 134. Bausch Health Recent Developments
Table 135. Alnylam Company Information
Table 136. Alnylam Business Overview
Table 137. Alnylam Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 138. Alnylam Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 139. Alnylam Recent Developments
Table 140. Acrotech Biopharma Company Information
Table 141. Acrotech Biopharma Business Overview
Table 142. Acrotech Biopharma Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026) & (US$ Million)
Table 143. Acrotech Biopharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
Table 144. Acrotech Biopharma Recent Developments
Table 145. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Image
Figure 5. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 6. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Share by Type: 2025 VS 2032
Figure 7. Liposomes Drugs Product
Figure 8. Lipid Nanoparticle Drugs Product
Figure 9. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 10. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Share by Application: 2025 VS 2032
Figure 11. Hospital Product
Figure 12. Retail Pharmacy Product
Figure 13. Other Product
Figure 14. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 15. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size, (US$ Million), 2021 VS 2025 VS 2032
Figure 16. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Share by Region: 2025 VS 2032
Figure 17. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Share by Players in 2025
Figure 18. Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Manufacturers Established Date
Figure 19. Global Top 5 and 10 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Players Market Share by Revenue in 2025
Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 21. North America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 22. North America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Share by Country (2021-2032)
Figure 23. United States Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 24. Canada Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 25. Mexico Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Share by Country (2021-2032)
Figure 26. Europe Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 27. Europe Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Share by Country (2021-2032)
Figure 28. Germany Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 29. France Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 30. U.K. Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 31. Italy Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 32. Spain Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 33. Russia Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 34. Netherlands Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 35. Nordic Countries Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 36. Asia-Pacific Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 37. Asia-Pacific Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Share by Country (2021-2032)
Figure 38. China Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 39. Japan Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 40. South Korea Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 41. India Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 42. India Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Share by Country (2021-2032)
Figure 43. Australia Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 44. China Taiwan Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 45. Southeast Asia Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 46. South America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 47. South America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Share by Country (2021-2032)
Figure 48. Brazil Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 49. Argentina Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 50. Chile Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 51. Colombia Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 52. Peru Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 53. Takeda Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 54. Teva Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 55. Sun Pharmaceutical Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 56. Johnson & Johnson Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 57. Chiesi Farmaceutici Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 58. Gilead Sciences Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 59. Zydus Cadila Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 60. TTY Biopharma Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 61. Sayre Therapeutics Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 62. Pacira Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 63. Luye Pharma Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 64. Leadiant Biosciences Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 65. Kinyond Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 66. Jazz Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 67. Ipsen Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 68. Fudan-Zhangjiang Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 69. CSPC Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 70. Bausch Health Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 71. Alnylam Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Figure 72. Acrotech Biopharma Revenue Growth Rate in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
Scope & coverage.
Types
- Liposomes Drugs
- Lipid Nanoparticle Drugs
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Takeda
- Teva
- Sun Pharmaceutical
- Johnson & Johnson
- Chiesi Farmaceutici
- Gilead Sciences
- Zydus Cadila
- TTY Biopharma
- Sayre Therapeutics
- Pacira
- Luye Pharma
- Leadiant Biosciences
- Kinyond
- Jazz
- Ipsen
- Fudan-Zhangjiang
- CSPC
- Bausch Health
- Alnylam
- Acrotech Biopharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Liposome and Lipid Nanoparticle Finished Pharmaceuticals by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Liposomes Drugs
- 2.2.3 Lipid Nanoparticle Drugs
- 2.3 Liposome and Lipid Nanoparticle Finished Pharmaceuticals by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Breakdown Data by Type
- 3.1 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Historic Market Size by Type (2021-2026)
- 3.2 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Forecasted Market Size by Type (2027-2032)
4 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Breakdown Data by Application
- 4.1 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Historic Market Size by Application (2021-2026)
- 4.2 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Perspective (2021-2032)
- 5.2 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Growth Trends by Region
- 5.2.1 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Historic Market Size by Region (2021-2026)
- 5.2.3 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Forecasted Market Size by Region (2027-2032)
- 5.3 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Dynamics
- 5.3.1 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Industry Trends
- 5.3.2 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Drivers
- 5.3.3 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Challenges
- 5.3.4 Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Liposome and Lipid Nanoparticle Finished Pharmaceuticals Players by Revenue
- 6.1.1 Global Top Liposome and Lipid Nanoparticle Finished Pharmaceuticals Players by Revenue (2021-2026)
- 6.1.2 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Revenue Market Share by Players (2021-2026)
- 6.2 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Liposome and Lipid Nanoparticle Finished Pharmaceuticals Head Office and Area Served
- 6.4 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Players, Product Type & Application
- 6.5 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Manufacturers Established Date
- 6.6 Global Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size (2021-2032)
- 7.2 North America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2021-2026)
- 7.4 North America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size (2021-2032)
- 8.2 Europe Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2021-2026)
- 8.4 Europe Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size (2021-2032)
- 9.2 Asia-Pacific Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size (2021-2032)
- 10.2 South America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2021-2026)
- 10.4 South America Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size (2021-2032)
- 11.2 Middle East & Africa Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Liposome and Lipid Nanoparticle Finished Pharmaceuticals Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.1.4 Takeda Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.2.4 Teva Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Sun Pharmaceutical
- 12.3.1 Sun Pharmaceutical Company Information
- 12.3.2 Sun Pharmaceutical Business Overview
- 12.3.3 Sun Pharmaceutical Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.3.4 Sun Pharmaceutical Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.3.5 Sun Pharmaceutical Recent Developments
- 12.4 Johnson & Johnson
- 12.4.1 Johnson & Johnson Company Information
- 12.4.2 Johnson & Johnson Business Overview
- 12.4.3 Johnson & Johnson Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.4.4 Johnson & Johnson Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.4.5 Johnson & Johnson Recent Developments
- 12.5 Chiesi Farmaceutici
- 12.5.1 Chiesi Farmaceutici Company Information
- 12.5.2 Chiesi Farmaceutici Business Overview
- 12.5.3 Chiesi Farmaceutici Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.5.4 Chiesi Farmaceutici Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.5.5 Chiesi Farmaceutici Recent Developments
- 12.6 Gilead Sciences
- 12.6.1 Gilead Sciences Company Information
- 12.6.2 Gilead Sciences Business Overview
- 12.6.3 Gilead Sciences Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.6.4 Gilead Sciences Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.6.5 Gilead Sciences Recent Developments
- 12.7 Zydus Cadila
- 12.7.1 Zydus Cadila Company Information
- 12.7.2 Zydus Cadila Business Overview
- 12.7.3 Zydus Cadila Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.7.4 Zydus Cadila Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.7.5 Zydus Cadila Recent Developments
- 12.8 TTY Biopharma
- 12.8.1 TTY Biopharma Company Information
- 12.8.2 TTY Biopharma Business Overview
- 12.8.3 TTY Biopharma Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.8.4 TTY Biopharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.8.5 TTY Biopharma Recent Developments
- 12.9 Sayre Therapeutics
- 12.9.1 Sayre Therapeutics Company Information
- 12.9.2 Sayre Therapeutics Business Overview
- 12.9.3 Sayre Therapeutics Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.9.4 Sayre Therapeutics Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.9.5 Sayre Therapeutics Recent Developments
- 12.10 Pacira
- 12.10.1 Pacira Company Information
- 12.10.2 Pacira Business Overview
- 12.10.3 Pacira Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.10.4 Pacira Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.10.5 Pacira Recent Developments
- 12.11 Luye Pharma
- 12.11.1 Luye Pharma Company Information
- 12.11.2 Luye Pharma Business Overview
- 12.11.3 Luye Pharma Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.11.4 Luye Pharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.11.5 Luye Pharma Recent Developments
- 12.12 Leadiant Biosciences
- 12.12.1 Leadiant Biosciences Company Information
- 12.12.2 Leadiant Biosciences Business Overview
- 12.12.3 Leadiant Biosciences Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.12.4 Leadiant Biosciences Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.12.5 Leadiant Biosciences Recent Developments
- 12.13 Kinyond
- 12.13.1 Kinyond Company Information
- 12.13.2 Kinyond Business Overview
- 12.13.3 Kinyond Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.13.4 Kinyond Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.13.5 Kinyond Recent Developments
- 12.14 Jazz
- 12.14.1 Jazz Company Information
- 12.14.2 Jazz Business Overview
- 12.14.3 Jazz Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.14.4 Jazz Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.14.5 Jazz Recent Developments
- 12.15 Ipsen
- 12.15.1 Ipsen Company Information
- 12.15.2 Ipsen Business Overview
- 12.15.3 Ipsen Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.15.4 Ipsen Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.15.5 Ipsen Recent Developments
- 12.16 Fudan-Zhangjiang
- 12.16.1 Fudan-Zhangjiang Company Information
- 12.16.2 Fudan-Zhangjiang Business Overview
- 12.16.3 Fudan-Zhangjiang Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.16.4 Fudan-Zhangjiang Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.16.5 Fudan-Zhangjiang Recent Developments
- 12.17 CSPC
- 12.17.1 CSPC Company Information
- 12.17.2 CSPC Business Overview
- 12.17.3 CSPC Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.17.4 CSPC Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.17.5 CSPC Recent Developments
- 12.18 Bausch Health
- 12.18.1 Bausch Health Company Information
- 12.18.2 Bausch Health Business Overview
- 12.18.3 Bausch Health Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.18.4 Bausch Health Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.18.5 Bausch Health Recent Developments
- 12.19 Alnylam
- 12.19.1 Alnylam Company Information
- 12.19.2 Alnylam Business Overview
- 12.19.3 Alnylam Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.19.4 Alnylam Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.19.5 Alnylam Recent Developments
- 12.20 Acrotech Biopharma
- 12.20.1 Acrotech Biopharma Company Information
- 12.20.2 Acrotech Biopharma Business Overview
- 12.20.3 Acrotech Biopharma Revenue in Liposome and Lipid Nanoparticle Finished Pharmaceuticals Business (2021-2026)
- 12.20.4 Acrotech Biopharma Liposome and Lipid Nanoparticle Finished Pharmaceuticals Product Portfolio
- 12.20.5 Acrotech Biopharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$2,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst